RECRUITING

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Talk to us

Conditions

Irritable Bowel SyndromeIrritable Bowel Syndrome With DiarrheaIBS

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.

Official Title

The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS

Quick Facts

Study Start:2020-01-09
Study Completion:2025-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03729271

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * IBS-D (Rome IV Diagnostic Criteria)
  2. * Diary compliance for at least 5 days and no rescue medications during baseline
  3. * Appropriate levels of abdominal pain and diarrhea
  1. * Pregnant women or planning on becoming pregnant while in the study, or lactating women while in the study
  2. * Inflammatory bowel disease, diabetes mellitus, systemic sclerosis, or celiac disease
  3. * Active gastrointestinal or hematological malignancy which requires ongoing treatment
  4. * Surgery to the GI tract in the past 3 months
  5. * Gastrointestinal infection or diverticulitis in the past 3 months
  6. * Severe hepatic impairment
  7. * Any use of antibiotics in the past month
  8. * Current use of probiotics
  9. * Any history of allergies to rifaximin or its derivatives
  10. * Any comitant use of P-glycoprotein inhibitors (for example. Cyclosporine)
  11. * Known allergies to glucose or lactulose

Contacts and Locations

Study Contact

Borko Nojkov, MD
CONTACT
734-936-9455
bnojkov@med.umich.edu
William Chey, M.D.
CONTACT
734-936-4775
wchey@med.umich.edu

Principal Investigator

William Chey, M.D.
PRINCIPAL_INVESTIGATOR
University of Michigan

Study Locations (Sites)

University of Michigan
Ann Arbor, Michigan, 48109
United States

Collaborators and Investigators

Sponsor: University of Michigan

  • William Chey, M.D., PRINCIPAL_INVESTIGATOR, University of Michigan

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-09
Study Completion Date2025-01-01

Study Record Updates

Study Start Date2020-01-09
Study Completion Date2025-01-01

Terms related to this study

Keywords Provided by Researchers

  • IBS
  • Irritable Bowel Syndrome

Additional Relevant MeSH Terms

  • Irritable Bowel Syndrome
  • Irritable Bowel Syndrome With Diarrhea